Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres
Clémence Lacroix(Inserm), A.‐P. Jonville‐Béra(Université de Tours), Michel Mallaret(Centre Hospitalier Universitaire de Grenoble)
Cited by 12
Related Papers
Drug‐induced peripheral oedema: An aetiology‐based review
|British Journal of Clinical Pharmacology|2021|82
French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic
|European Annals of Otorhinolaryngology Head and Neck Diseases|2020|76
Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database
|Journal of the Neurological Sciences|2019|60
Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions
|Clinical Pharmacology & Therapeutics|2021|48
Non-targeted screening for novel psychoactive substances among agitated emergency department patients
|Clinical Toxicology|2016|42